Chinese cardiovascular firm Sihuan heads for Hong Kong IPO
This article was originally published in Scrip
The Chinese company Sihuan Pharmaceutical Holdings Group is aiming to raise up to $816 million through an initial public offering in Hong Kong, which it will use mainly to fund mergers and acquisitions and to bolster R&D.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.